Sara Saberi

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Iacopo Olivotto, Artur Oręziak, Roberto Barriales‐Villa et al. · The Lancet · 2020 · 1.1K citations · Full text

Cardiomyopathy, Structural Heart Disease, Cardiovascular Disease +2

2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines

Steve R. Ommen, Carolyn Y. Ho, Irfan M. Asif et al. · Circulation · 2024 · 494 citations

Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy

Carolyn Y. Ho, Matthew E. Mealiffe, Richard G. Bach et al. · Journal of the American College of Cardiology · 2020 · 316 citations · Full text

2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy

Steve R. Ommen, Carolyn Y. Ho, Irfan M. Asif et al. · Journal of the American College of Cardiology · 2024 · 249 citations

Cardiomyopathy, Cardiovascular Disease, Hypertrophic Cardiomyopathy +5

Effect of Moderate-Intensity Exercise Training on Peak Oxygen Consumption in Patients With Hypertrophic Cardiomyopathy

Sara Saberi, Matthew T. Wheeler, Jennifer L. Bragg‐Gresham et al. · JAMA · 2017 · 225 citations · Full text